search icon

    Market Snapshot

    blog search icon

    Kymera Therapeutics, Inc. Stock Ratios, Return on Equity and Profit Margin

    Kymera Therapeutics, Inc.

    (NASDAQ:KYMR)

    $36.85

    1.37 (3.86%)

    At Close: 4:00 PM

    $-

    - (-%)

    Pre Market: 4:00 AM

    KYMR Financial

    Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.

    Quick Ratio

    5.40

    Enterprise Value/Revenue

    -

    Fiscal Year Ends

    Dec

    Current Ratio

    5.40

    Peg Ratio (5 yr Expected)

    -

    Enterprise Value/EBITDA

    -

    Most Recent Quarter (MRQ)

    Jun. 2022

    Next Earning Date

    2022-11-03

    Profit Margin

    -

    Revenue (TTM)

    56.75 Million

    Quarterly Revenue Growth (YOY)

    -52.70%

    Operating Margin (TTM)

    -

    Revenue Per Share (TTM)

    1.10

    SALES GROWTH PAST 5Y

    -

    Operating Margin

    (TTM)

    -

    Profit Margin

    -

    Revenue

    (TTM)

    56.8 Million

    Revenue Per Share

    (TTM)

    1.10

    Return & Ratios

    It is true that no indicator can be relied on to predict company health 100% of the time. However, a number of indicators can provide insight into trading trends. A number of ratios can measure a company's strength, both in comparison to its peers and to its past performance. A number of ratios can be used to measure the performance of an organization, such as the Return On Investment (ROI), Return On Assets (ROA) as well as Return On Equity (ROE).

    Gross Margin

    -

    Return on Investment (TTM)

    -21.80%

    Return on Equity (TTM)

    -34.20%

    Gross Profit (TTM)

    -

    Return on Assets (TTM)

    -26.40%

    Net Income AVI To Common (TTM)

    0

    EBITDA

    0

    DILUTED EPS (TTM)

    -2.94

    Quarterly Earnings Growth (YOY)

    -39.90%

    Graph For Net Income

    Graph For EBITDA

    Cash & Equity Ratios

    Total Cash (MRQ)

    392.31 Million

    Total Debt (MRQ)

    17.29 Million

    Book Value Per Share (MRQ)

    9.43

    Levered Free Cash Flow (TTM)

    0

    Total Cash Per Share (MRQ)

    9.43

    Total Debt/Equity (MRQ)

    0

    Operating Cash Flow (TTM)

    0

    Total Cash

    Total Cash Per Share

    Book Value Per Share

    Operating Cash Flow

    Frequently Asked Questions

    icon

    When was the last time Kymera Therapeutics, Inc. (NASDAQ:KYMR) reported earnings?

    Kymera Therapeutics, Inc. (KYMR) published its most recent earnings results on Nov. 2022 for the quarter ended Jun. 2022.

    icon

    What is Kymera Therapeutics, Inc.'s current ROE?

    An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Kymera Therapeutics, Inc. (NASDAQ:KYMR)'s trailing twelve month ROE is -34.20%.

    icon

    What are ROA and ROI telling us?

    It is sometimes helpful for shareholders to know how their investments are doing. Return on investment (ROI) for Kymera Therapeutics, Inc. (KYMR) is -21.80%. As ROI percentages rise, profits exceed costs, thus analysts consider such investments to be a general win.  In contrast, the Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Kymera Therapeutics, Inc. (KYMR) currently has a ROA of -26.40% Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.

    icon

    Where did KYMR's net profit margin stand at?

    KYMR reported a profit margin of N/A in the last quarter ended Jun. 2022. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.

    icon

    When will Kymera Therapeutics, Inc.'s next earnings report be released?

    Although Kymera Therapeutics, Inc. has not yet announced its next earnings date, it is expected to be, Nov. 3, 2022 based on last year's announcement date.

    icon

    What is KYMR's short-term liquidity position?

    According to Kymera Therapeutics, Inc. (KYMR)'s current performance indicators, the Quick Ratio of 5.40 in the last reported quarter. The current ratio of KYMR stands at 5.40 in the last reported quarterand a Debt/Eq ratio of 0.